Abstract:BACKGROUND:Vascular growth followed by vessel specification is crucial for the establishment of a hierarchical blood vascular network. We have shown that TIE2 is required for vein development while little is known about its homologue TIE1 (tyrosine kinase with immunoglobulin-like and EGF [epithelial growth factor]-like domains 1) in this process. METHODS:We analyzed functions of TIE1 as well as its synergy with TIE2 in the regulation of vein formation by employing genetic mouse models targeting Tie1, Tek, and Nr2f2, together with in vitro cultured endothelial cells to decipher the underlying mechanism. RESULTS:Cardinal vein growth appeared normal in TIE1-deficient mice, whereas TIE2 deficiency altered the identity of cardinal vein endothelial cells with the aberrant expression of DLL4 (delta-like canonical Notch ligand 4). Interestingly, the growth of cutaneous veins, which was initiated at approximately embryonic day 13.5, was retarded in mice lack of TIE1. TIE1 deficiency disrupted the venous integrity, displaying increased sprouting angiogenesis and vascular bleeding. Abnormal venous sprouts with defective arteriovenous alignment were also observed in the mesenteries of Tie1-deleted mice. Mechanistically, TIE1 deficiency resulted in the decreased expression of venous regulators including TIE2 and COUP-TFII (chicken ovalbumin upstream promoter transcription factor, encoded by Nr2f2, nuclear receptor subfamily 2 group F member 2) while angiogenic regulators were upregulated. The alteration of TIE2 level by TIE1 insufficiency was further confirmed by the siRNA-mediated knockdown of Tie1 in cultured endothelial cells. Interestingly, TIE2 insufficiency also reduced the expression of TIE1. Combining the endothelial deletion of Tie1 with 1 null allele of Tek resulted in a progressive increase of vein-associated angiogenesis leading to the formation of vascular tufts in retinas, whereas the loss of Tie1 alone produced a relatively mild venous defect. Furthermore, the induced deletion of endothelial Nr2f2 decreased both TIE1 and TIE2. CONCLUSIONS:Findings from this study imply that TIE1 and TIE2, together with COUP-TFII, act in a synergistic manner to restrict sprouting angiogenesis during the development of venous system.

Therapeutic targeting of the angiopoietin–TIE pathway

Endothelial TIE1 Restricts Angiogenic Sprouting to Coordinate Vein Assembly in Synergy with Its Homologue TIE2

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data

Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases

The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye

[The Regulating Roles of Angiopoietins/tek-2 in Angiogenesis].

TAK1 signaling is a potential therapeutic target for pathological angiogenesis

Angiopoietin-2 promotes inflammatory lymph angiogenesis and its effect can be blocked by the specific inhibitor L1-10

Current progress in structure and function of angiopoietin family

Controlling Angiogenesis by Two Unique TGF-β Type I Receptor Signaling Pathways.

Endothelial destabilization by angiopoietin-2 via integrin β1 activation

Data from Angiopoietin-1 Overexpression Modulates Vascular Endothelium to Facilitate Tumor Cell Dissemination and Metastasis Establishment

THE ROLE OF ANG / TIE SIGNALING IN LYMPHANGIOGENESIS

Regulators of angiogenesis and strategies for their therapeutic manipulation

The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation

TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy

Angiopoietin-Tie Signaling in Kidney Diseases: an Updated Review

Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease

Thrombospondin-based Antiangiogenic Therapy

Recent Progress in Study of Angiopoietin in Tumor Treatment